Key Points
Key points are not available for this paper at this time.
Abstract
The incidence of diabetes is increasing, but that of diabetic retinopathy is falling, probably owing to better management of glucose levels, lipid abnormalities, and hypertension. Clinical trials of VEGF and PPAR-α inhibitors are improving vision and providing insights into pathogenesis.
Cite This Study
Antonetti et al. (2012) studied this question.